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Abstract
The endocannabinoid 2-arachidonoylglycerol (2-AG) is a lipid mediator
involved in various physiological processes. In response to neural activity,
2-AGissynthesizedpost-synaptically,thenactivatespre-synapticcannabinoid
CB1receptors(CB1Rs)inaretrogrademanner,resultingintransientandlong-
lasting reduction of neurotransmitter release. The signalling competence of
2-AG is tightly regulated by the balanced action between ‘on demand’ bio-
synthesis and degradation. We review recent research on monoacylglycerol
lipase (MAGL), ABHD6 and ABHD12, three serine hydrolases that together
account for approx. 99% of brain 2-AG hydrolase activity. MAGL is
responsibleforapprox.85%of2-AGhydrolysisandcolocalizes withCB1R in
axon terminals. It is therefore ideally positioned to terminate 2-AG-CB1R
signalling regardless of the source of this endocannabinoid. Its acute phar-
macological inhibition leads to 2-AG accumulation and CB1R-mediated
behavioural responses. Chronic MAGL inactivation results in 2-AG overload,
desensitization of CB1R signalling and behavioural tolerance. ABHD6
accounts for approx. 4% of brain 2-AG hydrolase activity but in neurones it
rivals MAGL in efﬁcacy. Neuronal ABHD6 resides post-synaptically, often
juxtaposed with CB1Rs, and its acute inhibition leads to activity-dependent
accumulation of 2-AG. In cortical slices, selective ABHD6 blockade facilitates
CB1R-dependent long-term synaptic depression. ABHD6 is therefore posi-
tionedtoguardintracellularpoolsof2-AGatthesiteofgeneration.ABHD12is
highlyexpressedinmicrogliaandaccountsforapprox.9%oftotalbrain2-AG
hydrolysis. Mutations in ABHD12 gene are causally linked to a neurodegen-
erative disease called PHARC. Whether ABHD12 qualiﬁes as a bona ﬁde
member to the endocannabinoid system remains to be established.
Keywords 2-AG hydrolase, ABHD12, ABHD6, endocannabinoid, monoa-
cylglycerol lipase, a/b-hydrolase domain.
Lipid molecules not only serve as building blocks of the
central nervous system (CNS) but are being increasingly
appreciated as physiological mediators of signal trans-
duction. Molecular components of the lipid signalling
machineries show promise as therapeutic targets for
various diseases. In contrast with peripheral tissues,
brain tissue is enriched in polyunsaturated fatty acids
(PUFAs), in particular arachidonic acid (AA, 20:4n-6)
and docosahexanoid acid (DHA, 22:6n-3). These long-
chain PUFAs are needed for normal brain development
and function. Endocannabinoids are endogenous
AA-containing lipid mediators involved in the regula-
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processes, including neurotransmission, mood, appetite,
nociception, addiction, inﬂammation, peripheral metab-
olism and reproduction (Freund et al. 2003, Piomelli
2003, Di Marzo et al. 2007, Kano et al. 2009). The eCB
system consists of two G protein-coupled cannabinoid
receptors (CB1R and CB2R), their endogenous activat-
ing ligands (the eCBs), as well as enzymes involved in
the biosynthesis and inactivation of these ligands. The
two well-characterized eCBs, N-arachidonoylethanol-
amine (anandamide, AEA) and 2-arachidonoylglycerol
(2-AG), bind to and activate both CB1R and CB2R with
somewhat distinct potencies and efﬁcacies. When tested
under comparable assay conditions, 2-AG is more
potent than AEA and behaves a full agonist at both
receptor subtypes (Sugiura et al. 2006). In addition,
AEA can activate the vanilloid receptor TRPV1, a
member of the transient receptor potential family
of cation channels that mediates pain sensation
(De Petrocellis & Di Marzo 2009). Besides CB1R and
CB2R, an orphan G protein-coupled receptor (GPCR),
termed GPR55, has been identiﬁed and often referred to
as the third putative (or atypical) cannabinoid receptor.
However, the pharmacology of this receptor is still
controversial and an increasing body of evidence
suggests that the non-cannabinoid lipid lysophosphat-
idylinositol, rather than AEA or 2-AG, acts as the
cognate agonist of this receptor (Pertwee et al. 2010).
The purpose of this review is to cover recent research
that has advanced our understanding on the physiolog-
ical regulation of the level and signalling competence of
2-AG through the CBRs. The focus will be on MAGL,
ABHD6 and ABHD12, the three serine hydrolases that
together account for approx. 99% of 2-AG hydrolysis
in the CNS.
Physiology and logic of the eCB system in the
CNS
The discovery of CBRs and their endogenous ligands
has greatly accelerated research on cannabinoid actions
in the brain. Indeed, CB1R is among the most abun-
dantly expressed and widely distributed GPCR in the
brain (Herkenham et al. 1991) (Fig. 1). CB1R unlikely
evolved merely to mediate the ‘bliss’ attributed to
delta9-tetrahydrocannabinol (THC), the major psycho-
active component of Cannabis sativa, nor does nature
maintain protein synthesis just for reserve. Instead, the
abundance of CB1R in speciﬁc types of neurones and its
enrichment into pre-synaptic terminals throughout the
brain strongly suggests that CB1R evolved speciﬁcally
to mediate eCB signalling. It is now well established
that in response to neural activity, eCBs are produced
‘on demand’ and released from post-synaptic neurones,
then activate pre-synaptic CB1Rs in a retrograde
manner, resulting in transient and long-lasting reduc-
tion of neurotransmitter release at various central
synapses (Alger 2002, Freund et al. 2003, Piomelli
2003, Kano et al. 2009). Such a retrograde signalling
mode has established a new concept how diffusible lipid
Figure 1 Functional autoradiography reveals wide distribution of CB1R-Gi signalling axis in the central nervous system. The
method utilizes the radio-labelled GTP analogue [
35S]GTPcS that incorporates into activated heterotrimeric G proteins in cell
membrane following stimulation of Gi-coupled receptors, either with exogenous or endogenous agonists (Laitinen 2004). The image
on the left depicts basal G protein activity in the absence of added agonists and with tonic adenosine A1 receptor signal occluded. In
the middle panel, CB1Rs were stimulated using the potent synthetic cannabinoid agonist CP55,940. The brain regions with
activation of CB1R-Gi axis include the caudate putamen (Cpu), the cerebral cortex (Cx), the hippocampus (Hi), and the molecular
layer of cerebellum (Cbm), closely matching CB1R distribution pattern obtained by classical receptor autoradiography (Herkenham
et al. 1991). In the panel at right, pre-treatment of brain sections with the broad spectrum irreversibly acting serine hydrolase
inhibitor methylarachidonylﬂuorophosphonate (MAFP) results in endogenous 2-arachidonoylglycerol (AG) accumulation and
2-AG-dependent CB1R activity throughout the CB1R-responsive brain regions. Previous studies (Paloma ¨ki et al. 2007) have
demonstrated that (1) the responses to CP55,940 and MAFP are fully blocked by the CB1R-selective antagonist AM251, (2) the
MAFP response is not mimicked by selective inhibitor of fatty acid amide hydrolase, ruling our any contribution of AEA, (3) MAFP
does not directly activate CB1Rs and 4) MS–GC analysis indicated elevated 2-AG levels in MAFP-treated sections.
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provide both short- and long-term ﬁne-tuning of
synaptic efﬁcacy and neural activity. Electrophysiolo-
gists have found robust modulation of synaptic plastic-
ity and thus introduced new terminology, such as
depolarization-induced suppression of excitation
(DSE), and depolarization-induced suppression of inhi-
bition (DSI), both of which are best explained by short-
term retrograde eCB signalling inhibiting synaptic
release of glutamate and GABA respectively (Kano
et al. 2009) (Fig. 2). The presence of molecules of the
eCB system, such as the eCBs, CB1R, as well as enzymes
involved in eCB metabolism of during neuronal devel-
opment have been linked to neuronal proliferation,
differentiation, migration, axon guidance and synapto-
genesis (Bisogno et al. 2003, Keimpema et al. 2010,
Argaw et al. 2011). Thus, the eCBs are intimately
involved in the physiology of the nervous system.
Activity-dependent cleavage of membrane
phospholipids for retrograde eCB-GPCR
signalling
Biosynthesis and release of 2-AG can be induced by
either depolarization or activation of Gq-coupled
GPCRs, typically group I metabotropic glutamate
receptors (mGluR1 or mGluR5) or M1/M3 muscarinic
acetylcholine receptors (Hashimotodani et al. 2005,
Kano et al. 2009). In the hippocampus, 2-AG release
is markedly enhanced by simultaneous depolarization
and input via Gq-coupled receptors, a phenomenon
where PLC-b1 is suggested to serve as the coincidence
detector (Hashimotodani et al. 2005). The physiologi-
cal signiﬁcance of the coincidence detection is that such
a mechanism allows simultaneous sensing of both
pre-synaptic (transmitter release) and post-synaptic
(membrane depolarization) activities through the Ca
2+
dependency of PLC-b1 (Hashimotodani et al. 2005). In
principle, PLC activity generates two second messen-
gers, IP3 that triggers Ca
2+ release from intracellular
stores, and diacylglycerol (DAG) that classically acti-
vates protein kinase C. In brain regions endowed for
eCB signalling, sn-2-arachidonoyl-containing DAG spe-
cies are hydrolysed by sn-1-speciﬁc lipase (DAGL) to
generate 2-AG, the major eCB in brain. Two sn-1-
speciﬁc DAGL isoforms have been cloned, namely
DAGLa and DAGLb (Bisogno et al. 2003). The cellular
expression of the two isoforms was demonstrated to
closely reﬂect 2-AG biosynthesis and release. During
neuronal development, localization of DAGLa and
DAGLb changes from pre- to post-synaptic elements,
i.e. from axonal tracts in the embryo to dendritic ﬁelds
in the adult, closely matching with the developmental
changes in need for 2-AG synthesis from the pre- to the
post-synaptic compartment (Bisogno et al. 2003). Over-
expression of DAGLa in mouse neuroblastoma cells
results in 2-AG accumulation, whereas knockdown of
DAGLa by RNA interference blunts 2-AG production
and prevents group I mGluR-stimulated production of
this eCB (Jung et al. 2007). A docking platform for
efﬁcient coupling of glutamatergic signalling to 2-AG
biosynthesis is provided by scaffolds such as Homer
proteins that allow interaction of group I mGluRs with
the PPxxF domain of DAGLa (Jung et al. 2007).
Interestingly, DAGLb, which based on recent gene
ablation studies is not involved in 2-AG generation for
retrograde signalling (Gao et al. 2010, Tanimura et al.
2010), also lacks the Homer-interacting PPxxF domain
(Jung et al. 2007). Collectively, these studies suggest
that DAGLa has speciﬁcally evolved to generate 2-AG
for retrograde synaptic signalling. Two recent studies
using DAGL-knockout (DAGL-KO) mice have pro-
vided strong additional support to this idea. DAGLa-
KO mice were found to have marked (up to 80%)
Figure 2 Activity-dependent generation of 2-arachidonoyl-
glycerol (2-AG) for retrograde signalling. Depolarization-
induced suppression of inhibition (DSI) is one of the best
characterized forms of short-term synaptic plasticity where
neuronal activity evokes post-synaptic depolarization via
excitatory glutamatergic (Glu) action. This initiates signalling
events in the post-synaptic membrane leading to 2-AG bio-
synthesis and release (dashed arrow). In the retrograde mode of
signalling, 2-AG activates pre-synaptic CB1Rs, which are
particularly enriched on the inhibitory GABAergic terminals.
CB1R-Gi signalling results in transient suppression of GABA
release. Similar endocannabinoid feedback mechanism oper-
ates also at the excitatory synapse where 2-AG-CB1R signal-
ling evokes a cellular response, known as depolarization-
induced suppression of excitation (DSE) (adapted and modiﬁed
from Uchigashima et al. (2007)). Note the relative enrichment
of CB1Rs on the GABAergic terminals as opposed to the
glutamatergic terminals. The relative size of the two sparks
illustrates the fact that the stimulation thresholds needed to
evoke DSI are generally much lower than those needed to
observe DSE (Kano et al. 2009, Yoshida et al. 2011).
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concomitant decrease in AA levels, whereas DAGLb-
KO animals exhibited either no (Tanimura et al. 2010)
or up to 50% reduction (Gao et al. 2010) in brain 2-AG
levels. Importantly, several forms of retrograde eCB-
mediated synaptic suppression, such as DSE and DSI,
were absent from the tested brain regions (hippocam-
pus, cerebellum and striatum) of DAGLa-KO mice but
appeared intact in DAGLb-KO mice brains (Gao et al.
2010, Tanimura et al. 2010). There was no evidence for
compensatory changes of DAGLb in DAGLa-KO mice
or vice versa, nor was there evidence for abnormal
expression patterns or protein levels of other molecular
components of the eCB signalling machinery. Interest-
ingly, eCB control of neurogenesis in the adult hippo-
campus was compromised in both DAGLa- and
DAGLb-KO mice, as well as in the subventricular zone
of DAGLa-KO animals (Gao et al. 2010). In peripheral
tissues such as the liver, DAGLb seems to be the major
isoform generating 2-AG (Gao et al. 2010). Collec-
tively, the genetic studies suggest that DAGLa is the
major biosynthetic enzyme generating 2-AG for retro-
grade signalling. It is interesting to note that in some
brain regions highly enriched with the CB1R (such as
the substantia nigra), immunohistochemistry reveals
only sparse labelling with the DAGLa antibodies
(Uchigashima et al. 2007, Kano et al. 2009, Tanimura
et al. 2010). This would suggest that alternative bio-
chemical routes for 2-AG biosynthesis (Sugiura et al.
2006, Kano et al. 2009) are utilized to generate the
CB1R-activating eCB in brain regions with sparse
DAGLa expression. Further studies with the DAGL-
KO mice should shed more light on this issue.
Synaptic architecture of the eCB signalling
machinery for retrograde 2-AG signalling
In situ hybridization studies combined with immuno-
histochemical studies with properly validated antibodies
have revealed the ultrastructural localization, molecular
composition and synaptic organization of the apparatus
needed for 2-AG-mediated retrograde signalling at
various central synapses. An excellent review covering
details of this topic is available (Kano et al. 2009) and
therefore only the general aspects are brieﬂy discussed
here. The emerging picture is strikingly similar regard-
less of the brain region and mammalian species studied.
At the glutamatergic hippocampal synapses of both
rodents and humans, DAGLa is concentrated in den-
dritic spine heads around the post-synaptic density
throughout the hippocampal formation, whereas CB1R
is strategically situated at the pre-synaptic axon termi-
nals on the opposite side of synaptic cleft (Katona et al.
2006, Kano et al. 2009, Luda ´nyi et al. 2011). In the
striatal medium spiny neurones, DAGLa and the Gq-
coupled GPCRs (mGluR5 and M1) are all enriched on
the somatodendritic surface (Uchigashima et al. 2007),
whereas CB1R localization is pre-synaptic and the
receptors are enriched on the GABAergic axon termi-
nals and relatively low abundance on the corticostriatal
glutamatergic terminals (Uchigashima et al. 2007).
Relative enrichment of DAGLa on the post-synaptic
membrane at glutamatergic synapses and CB1Rs at the
inhibitory terminals instead of excitatory terminals
seems to be one hallmark of retrograde eCB signalling
at various central synapses (Fig. 2). Such an arrange-
ment likely provides the neuroanatomical and physio-
logical basis for observations where the stimulation
thresholds required to evoke DSI are generally much
lower than those needed to observe DSE (Kano et al.
2009, Yoshida et al. 2011).
Termination of eCB signalling
By analogy to classical neurotransmission, the magni-
tude and duration of eCB signalling are tightly regulated
by the balanced action between the enzymes that
synthesize and hydrolyse these lipid messengers. The
hydrolysis of eCBs is principally carried out by four
enzymes belonging to the metabolic serine hydrolase
family. Solid experimental evidence supports the pri-
mary role of fatty acid amide hydrolase (FAAH) in the
inactivation of AEA both in vitro and in vivo (Ahn et al.
2009). Indeed, comprehensive inactivation of FAAH in
rodents either by genetic or pharmacological means
results in marked (>10-fold) elevations in brain AEA
levels, and as a consequence, CB1R-dependent analgesia
in various models of acute and chronic pain (Ahn et al.
2009). Importantly, no tolerance of CB1R function and
behavioural responses takes place after chronic FAAH
inactivation (Ahn et al. 2009, Schlosburg et al. 2010).
The serine hydrolases MAGL, ABHD6 and
ABHD12 as guardians of 2-AG signalling
through the CBRs
The major enzymatic route for 2-AG inactivation in
brain is via hydrolysis generating AA and glycerol as the
end products. MAGL was the ﬁrst hydrolase implicated
in 2-AG degradation both in vitro and in vivo (Dinh
et al. 2002, 2004, Saario et al. 2004, Labar et al.
2010b). In many tissues and cell types, MAGL is
detected both in soluble and membrane preparations.
Traditionally, MAGL functions as a key lipolytic
enzyme in the mobilization of lipid stores for fuel or
lipid synthesis. Accordingly, MAGL was originally
puriﬁed, and subsequently cloned from the adipose
tissue (Karlsson et al. 1997, Labar et al. 2010b).
A recent study has illuminated a pathophysiological,
eCB-independent role for MAGL as well. Activity-based
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identiﬁed MAGL overexpression as the key metabolic
switch orchestrating cancer cell malignancy by redirect-
ing lipids from storage sites towards biosynthesis of
cancer promoting signalling lipids such as eicosanoids
and lysophospholipids (Nomura et al. 2010). It was
only after discovery of the CBRs and their endogenous
ligands that MAGL was linked to the eCB system.
The use of pharmacological inhibitors has provided
important initial observations concerning brain 2-AG
hydrolases and this issue is brieﬂy touched here.
Methylarachidonylﬂuorophosphonate (MAFP) is among
the most potent MAGL inhibitors identiﬁed to date
(Saario et al. 2004, Savinainen et al. 2010). MAFP
inhibits MAGL irreversibly but lacks selectivity, as it
inhibits most members of the metabolic serine hydrolase
family. N-arachidonoylmaleimide (NAM) was devel-
oped as a potent, cysteine targeting irreversible inhibitor
of MAGL-like activity in rat cerebellar membranes
(Saario et al. 2005). In contrast to MAFP, which
comprehensively blocks brain 2-AG hydrolysis (Saario
et al. 2004), approx. 15% residual activity remained
after maximally effective concentration of NAM (Saario
et al. 2005). We now know that the NAM-resistant
activity is caused by the two novel serine hydrolases,
namely ABHD6 and ABHD12 (see below). Further
studies have indicated that when tested against the brain
serine hydrolase proteome, NAM is indeed rather
selective for MAGL (Blankman et al. 2007). Recently,
a new carbamate compound known as JZL184 was
introduced as a potent and speciﬁc MAGL inhibitor
(Long et al. 2009). Although the low nanomolar
potency of JZL184 has been called into question
(Savinainen et al. 2010), the selectivity of JZL184 for
MAGL over other brain serine hydrolases was convinc-
ingly demonstrated using ABPP, a powerful proteomic
tool allowing inhibitor activity proﬁling in complex
proteomes (Blankman et al. 2007). Thus, NAM and
JZL184 can now be used as speciﬁc pharmacological
tools to dissect out potential role of MAGL as a
regulator of 2-AG-CB1R signalling. Indeed, recent
studies utilizing these inhibitors both in vitro and
in vivo have provided compelling evidence for the
importance of MAGL as the major regulator of not only
brain 2-AG levels but also various CB1R-dependent
cellular and behavioural responses (Kano et al. 2009,
Long et al. 2009, Pan et al. 2009, Straiker et al. 2009,
Labar et al. 2010b).
Chronic MAGL inactivation results in 2-AG
overload, desensitization of CB1R signalling
and behavioural tolerance
Long-term disruption of MAGL was achieved either by
genetic ablation (MAGL-KO) or chronic treatment with
the MAGL-selective inhibitor JZL184 (Chanda et al.
2010, Schlosburg et al. 2010), and in both studies the
general outcome was similar. In contrast to the antin-
ociceptive effects typically observed after acute MAGL
inhibition (Kinsey et al. 2009, Long et al. 2009),
animals with chronic MAGL blockade had normal pain
responses in several pain models. Moreover, these mice
lacked several behavioural responses, such as hypother-
mia, hypomotility, or catalepsy, typically observed after
administration of cannabinoid agonists such as THC. In
addition, MAGL-KO mice had decreased body weight,
thus resembling the lean phenotype of CB1R-KO mice
or animals treated with CB1R antagonists such as
rimonabant (Di Marzo et al. 2001). Moreover, eCB-
mediated short-term synaptic suppression was compro-
mised (Schlosburg et al. 2010).
ChronicinactivationofMAGLdramaticallydecreased
the ability of the mice to hydrolyse 2-AG, resulting in
massive (>10-fold) increases in brain 2-AG levels. In
response to chronic 2-AG overload, compensatory
desensitization of brain eCB-CB1R signalling was evi-
dent, as both CB1R density (assessed by radioligand-
binding studies) and functional responses (assessed by
CB1R-dependent G-protein activation assays) were
attenuatedfollowingchronicMAGLinactivation(Chan-
da et al. 2010, Schlosburg et al. 2010). Functional
autoradiography revealed that in response to chronic
JZL184 administration, desensitization of CB1R signal-
ling was not observed in all brain regions but manifested
speciﬁcally in regions participating in pain perception
and processing (Schlosburg et al. 2010). Interestingly,
CB1R signalling remained intact in brain regions such as
the caudate putamen and globus pallidus. These regions
are associated with cannabinoid-induced cataplexy.
From the behavioural responses studied, cannabinoid-
induced cataplexy also showed minimal cross-tolerance
(Schlosburg et al. 2010). Collectively, these studies indi-
cate that MAGL is the primary hydrolase responsible for
terminating 2-AG signalling in the CNS and that chronic
2-AG overload desensitizes the 2-AG-CB1R signalling
axis in speciﬁc brain regions, leading to functional and
behavioural antagonism of the eCB system.
3D-structural insights into MAGL function and
substrate recruitment
In 2005, the ﬁrst homology model of MAGL was
presented based on 3D structure of chloroperoxidase
from Streptomyces lividans as the template (Saario et al.
2005). As a result of poor sequence homology between
MAGL and chloroperoxidase, the homology model
offered limited insights into the overall structure and
organization of MAGL protein. However, as the central
core of the a/b hydrolase superfamily members is highly
conserved, the model offered ﬁrst insights into the
 2011 The Authors
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H269), previously identiﬁed based on mutagenesis
studies (Karlsson et al. 1997). The model also suggested
that two cysteine residues (C208 and C242) were
located within a close distance from the active site
and it was suggested that one or both of these cysteines
were potential targets of the maleimide-based inhibitor
NAM (Saario et al. 2005). Site-directed mutagenesis
studies have provided experimental support for these
predictions (Labar et al. 2010a,b).
The crystal structure of MAGL was recently solved
and this was achieved independently by two laborato-
ries (Bertrand et al. 2010, Labar et al. 2010a). Labar
et al. solved the structure of human MAGL at 2.2 A ˚
resolution and interestingly, MAGL crystallized in this
study as a dimer. Bertrand et al. resolved the crystal
structure of human MAGL both in its apoenzyme form
and in complex with the potent covalent inhibitor
SAR629. As expected, protein folds conserved in the a/b
hydrolase superfamily were present also in the MAGL
structure. These include an eight-stranded b-sheet,
composed of seven parallel strands and one antiparallel
strand, surrounded by a helices. Moreover, a ﬂexible
cap domain covers the structurally conserved b-sheet
and a lid domain guards the entrance of a relatively
large, occluded hydrophobic tunnel (approx. 25 A ˚ in
length and approx. 8 A ˚ in width). The active site is
buried at the bottom of the tunnel. For a detailed
structural analysis and discussion (both of which are
beyond the scope of this review), the the original reports
are referred to the reader (Bertrand et al. 2010, Labar
et al. 2010a). However, in the context of physiological
regulation of 2-AG-CB1R signalling, some points
emerging from the 3D structures deserve further
discussion here. For instance, it is likely, although not
experimentally proven, that MAGL orientation is espe-
cially well-suited to recruit its substrate directly from
the lipid membrane (Fig. 3). The 3D structure also
points to the possibility that the glycerol formed in
2-AG hydrolysis might leave the scene through a narrow
hydrophilic tunnel, referred to as an ‘exit hole’
(Bertrand et al. 2010). Docking studies with 2-AG and
1(3)-AG indicate that the two isomers bind to the active
site in similar manner (Bertrand et al. 2010), thus
providing the molecular basis for earlier observations
that MAGL hydrolyses the two isomers at similar rates
(Saario et al. 2004).
ABHD6 as a guardian of 2-AG-CBR signalling
at the site of eCB generation
ABHD6 is a newly discovered post-genomic protein
and relative little is known on its physiological
functions. High expression of ABHD6 has been
reported in certain forms of tumours suggesting that
ABHD6 might serve a new diagnostic marker of these
tumours (Li et al. 2009, Max et al. 2009). However,
its knockdown in cancer cells did not inhibit tumour
cell growth (Max et al. 2009). Based on hydropathy
analysis and biochemical studies, ABHD6 appears to
be an integral membrane protein (Blankman et al.
2007) that possesses typical a/b-hydrolase family
ﬁngerprints such as the lipase motif (GHSLG) and a
Figure 3 Monoacylglycerol lipase (MAGL) is the prime
guardian of 2-arachidonoylglycerol-CB1R (2-AG-CB1R) sig-
nalling at the axon terminals. In response to neural activity,
2-AG is produced post-synaptically ‘on demand’ (Fig. 2) and
then diffuses across the synapse to activate the pre-synaptic
CB1Rs. It is not known whether 2-AG enters the CB1R ligand
binding pocket directly from the extracellular space (dashed
vertical down arrow) or via lateral diffusion after incorpora-
tion into plasma membrane (dashed horizontal left arrow)
(Hurst et al. 2010). CB1R activation leads to Gi-mediated
short- and long-term inhibition of neurotransmitter release.
Ultrastructural localization studies show that MAGL is mainly
pre-synaptic and often colocalizes with CB1R in the axon
terminals (Kano et al. 2009). MAGL is therefore ideally
positioned to terminate eCB-CB1R signalling regardless of the
source of 2-AG. Inactivation of 2-AG takes place once this lipid
messenger dissociates from the receptor and diffuses laterally
towards its executor (dashed horizontal right arrow). High-
lighted in the illustration are features that emerged from the
MAGL 3D structural data (Bertrand et al. 2010, Labar et al.
2010a). In the illustrated scenario, 2-AG faces its ﬁnal destiny
after dissociating from the CB1R, by entering through the
hydrophobic tunnel with its polar glycerol head properly
oriented towards the bottom to face the catalytic triad. It is
possible that AA may diffuse back to the membrane
compartment via the entrance tunnel, whereas glycerol may
leave the scene via a separate exit hole (not illustrated) that was
disclosed in the MAGL 3D structure.
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residues S246-D333-H372). The active site is pre-
dicted to face cell interior. Such an orientation
suggests that ABHD6 is well suited to guard the
intracellular pool of 2-AG (Fig. 4). A recent study
(Marrs et al. 2010) provided the ﬁrst evidence to link
ABHD6 as a bona ﬁde member to the eCB system by
demonstrating that ABHD6 controls the accumulation
and efﬁcacy of 2-AG at the CBRs. In neurones,
ABHD6 was detected both at mRNA and protein
level and its pharmacological inhibition led to activ-
ity-dependent accumulation of 2-AG in neuronal
cultures. In the mouse cortex, ABHD6 localization
in neurones was mainly post-synaptic, often juxta-
posed with the pre-synaptic CB1Rs. ABHD6 was
expressed also in many principal glutamatergic neu-
rones, some GABAergic inteneurones, as well as
astrocytes but not in resident microglia (Marrs et al.
2010). However, in a microglial cell line (BV-2),
ABHD6 was enriched in mitochondrial fraction and
its knockdown reduced the hydrolysis of 2-AG in
intact cells with concomitant sensitization of 2-AG-
stimulated and CB2R-dependent cell migration. In
murine cortical slices, pharmacological ABHD6 inhi-
bition facilitated the induction of CB1R-dependent
long-term synaptic depression by otherwise subthresh-
old stimulation. Interestingly, CB1R-dependent short-
term synaptic depression (DSI or DSE) remained
unaltered following ABHD6 inhibition. The postu-
lated physiological role of ABHD as a regulator of
2-AG levels at the site of production of this eCB is
schematically illustrated in Figure 4.
ABHD12 – a microglial 2-AG hydrolase with
poorly characterized function
Like ABHD6, ABHD12 is a recently identiﬁed post-
genomic protein with poorly deﬁned physiological
function. Its potential role as a brain 2-AG hydrolase
was revealed using ABPP with mouse brain proteome
and it was estimated that at the bulk brain level
ABHD12 accounts for approx. 9% of total 2-AG
hydrolase activity (Blankman et al. 2007). Currently,
2-AG is the only known substrate for ABHD12 but it
is possible that the enzyme utilizes also other
substrates. As far as we are aware, 2-AG hydrolase
activity is the only feature so far potentially linking
ABHD12 to the eCB system. Based on hydropathy
analysis and biochemical data, ABHD12 appears to
be an integral membrane protein whose active site is
predicted to face the lumen/extracellular space (Blank-
man et al. 2007). Typical a/b-hydrolase domain pro-
tein ﬁngerprints, including the lipase motif (GTSMG)
and catalytic triad (predicted amino acid residues
S148-D278-H306), are fully conserved both in rodent
and human ABHD12 primary structure. It was
recently reported that mutations in the ABHD12 gene
that are predicted to compromise catalytic activity
severely, are causally linked to a neurodegenerative
disease called PHARC (polyneuropathy, hearing loss,
ataxia, retinitis pigmentosa, and cataract) (Fisker-
strand et al. 2010). Based on this surprising ﬁnding,
the authors suggested that ABHD12 must perform
essential physiological functions in the nervous system
and that PHARC may serve as a human ABHD12 KO
model (Fiskerstrand et al. 2010). However, tissue
2-AG levels and metabolism were not explored in
this study and thus the possible connection to the eCB
system clearly requires further studies. Interestingly,
ABHD12 transcripts are highly expressed in various
brain regions and speciﬁcally in microglia, but are
also abundant in related cell types such as macro-
phages and osteoclasts (Fiskerstrand et al. 2010).
There is also increasing appreciation for the potential
role of the eCB system, and microglial CB2Rs in
particular, as regulators of immune function in the
CNS (Cabral et al. 2008). Thus, as schematically
illustrated in Figure 5, ABHD12 appears to be well
suited to guard 2-AG-CB2R signalling in brain
microglia as well as in related cell types of peripheral
tissues.
Figure 4 ABHD6 is strategically positioned to regulate 2-AG
levels at the site of its generation. ABHD6 is an integral
membrane protein localizing to the post-synaptic neuronal
membrane. The PLC-DAGLa pathway cleaves the membrane
phospholipid PIP2 to generate 2-AG for retrograde signalling
through pre-synaptic CB1Rs (Fig. 2). Immunohistochemical
studies indicate that in neurones ABHD6 localizes to sites of
2-AG generation, including post-synaptic dendrites of principal
glutamatergic neurones as well as some GABAergic interneu-
rones (Marrs et al. 2010). 3D structure of ABHD6 has not been
resolved but the catalytic triad (depicted as mouth) is predicted
to face the cytosol/intracellular membrane (Blankman et al.
2007).
 2011 The Authors
Acta Physiologica  2011 Scandinavian Physiological Society, doi: 10.1111/j.1748-1716.2011.02280.x 273
Acta Physiol 2012, 204, 267–276 J R Savinainen et al.Æ The three guardians of 2-AG signallingConcluding ideas and possible directions for
future research
Delicate physiological regulatory mechanisms have
evolved to maintain the balance between the ‘on
demand’ biosynthesis and degradation of the signalling
competent pool of 2-AG in the CNS. Signiﬁcant progress
has been made during the last few years in dissecting out
details of the synaptic architecture and molecular
components of the eCB system intimately involved in
the physiology and function of the nervous system.
Recent milestones include the elucidation of MAGL
crystal structure, as well as the availability of selective
pharmacological and genetic tools to speciﬁcally target
key enzymes involved in the generation (DAGLa) and
degradation (MAGL) of 2-AG. Insights into MAGL
crystal structure open new avenues to exploit MAGL
function in further detail. From the perspective of
rational drug design, the shape of the hydrophobic
tunnel leading to the catalytic site suggests ‘a high
druggability of the protein’ (Bertrand et al. 2010),
offering possibilities for further development of potent
and speciﬁc MAGL inhibitors. However, one may ask
the question whether there is further need for such
inhibitors as potential therapeutics. The answer might be
yes if we consider the recently disclosed pathophysio-
logical role of MAGL in promoting cancer cell malig-
nancy (Nomura et al. 2010). In addition, speciﬁc
pharmacological tools are needed to explore MAGL
function further. On the other hand,the answer might be
no if we consider MAGL inhibitors as potential thera-
peutics to alleviate pain, for example. Direct CBR1
agonists like THC produce analgesia in various pain
models but their therapeutic use is limited because of
undesired psychotropic effects. Prolonging and amplify-
ing the eCB tone by inhibiting their enzymatic metab-
olism has therefore emerged as an alternative strategy to
manipulate the eCB system for possible clinical beneﬁt
(Lambert & Fowler 2005, Mackie 2006, Hohmann
2007, Saario & Laitinen 2007, Petrosino & Di Marzo
2010). We have just learnt that chronic MAGL inhibi-
tion leads to 2-AG overload and functional antagonism
of the eCB system, both at the molecular and behavio-
ural level (Lichtman et al. 2010). Would partial MAGL
inhibition result in pain relief without desensitization of
the eCB system? Might FAAH be a better molecular
target of the eCB system for pain relief? This reasoning is
supported by ﬁndings that the analgesic effects of a
FAAH inhibitor persist after long-term administration
and no apparent desensitization of CB1R function takes
place after chronic FAAH inactivation (Ahn et al. 2009,
Schlosburg et al. 2010). We know very little on the
physiological or pathophysiologicalroles ofABHD6 and
ABHD12. The postulated causal link between ABHD12
mutations and the neurodegenerative disease PHARC
should stimulate further research that will clarify
whether ABHD12 is a molecular component of the
eCB system. As always, new important ﬁndings tend to
raise more questions than to provide ﬁnal answers. This
in mind it appears that researchers on the eCB ﬁeld will
be busy also during the forthcoming years.
Figure 5 Hypothetical scheme where ABHD12 functions as
an ectohydrolase regulating extracellular 2-AG levels and
CB2R signalling in microglia. ABHD12 is predicted to be an
integral membrane protein (Blankman et al. 2007) and in the
brain its mRNA is highly expressed in microglia. ABHD12
transcripts are also found in related cell types (macrophages,
osteoclasts) and this hydrolase is therefore potentially posi-
tioned to guard 2-AG-CBR signalling in these cells. Although
ABHD12 hydrolyses 2-AG, it is not currently known whether it
utilizes other substrates and serve other functions. At the bulk
brain level, ABHD12 accounts for approx. 9% of total 2-AG
hydrolase activity. The 3D structure of ABHD12 is not avail-
able but the active site (depicted as a mouth digesting 2-AG) is
predicted to face the luminal/extracellular side. ABHD12 may
thus function as an ectohydrolase. In the hypothetical scenario,
ABHD12 guards extracellular 2-AG levels and subsequent
CB2R activity. 2-AG may enter the CB2R ligand binding
pocket directly from the extracellular space (dashed vertical
down arrow), or as suggested based on molecular dynamics
stimulation (Hurst et al. 2010), via lateral diffusion after
incorporation into the membrane (dashed horizontal left
arrow). CB2R activation leads to Gi-mediated cellular
responses such as proliferation and migration (Cabral et al.
2008). Inactivating ABHD12 mutations have been casually
linked to a neurodegenerative condition known as PHARC
(polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and
cataract) (Fiskerstrand et al. 2010). It is not currently known
whether this condition is directly linked to the endocannabi-
noid system.
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